| Literature DB >> 33042476 |
Koko Asakura1,2, Scott R Evans3, Toshimitsu Hamasaki2,3.
Abstract
We discuss using prediction as a flexible and practical approach for monitoring futility in clinical trials with two co-primary endpoints. This approach is appealing in that it provides quantitative evaluation of potential effect sizes and associated precision, and can be combined with flexible error-spending strategies. We extend prediction of effect size estimates and the construction of predicted intervals to the two co-primary endpoints case, and illustrate interim futility monitoring of treatment effects using prediction with an example. We also discuss alternative approaches based on the conditional and predictive powers, compare these methods and provide some guidance on the use of prediction for better decision in clinical trials with co-primary endpoints.Entities:
Keywords: Conditional Power; Group-sequential designs; Interim analyses; Predicted intervals; Predictive Power; Type I error
Year: 2019 PMID: 33042476 PMCID: PMC7539647 DOI: 10.1080/19466315.2019.1677494
Source DB: PubMed Journal: Stat Biopharm Res ISSN: 1946-6315 Impact factor: 1.452